EMEA-002141-PIP01-17-M01

Key facts

Active substance
Crizanlizumab
Therapeutic area
Haematology-Hemostaseology
Decision number
P/0060/2019
PIP number
EMEA-002141-PIP01-17-M01
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of sickle cell disease
Route(s) of administration
Intravenous use
Contact for public enquiries
Novartis Europharm Limited

Tel. +41 6132 41111
E-mail: paediatric.enquiries@novartis.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating